On Apr 17, we reaffirmed our long-term Neutral recommendation on Walgreen Co. (WAG) following the mixed second-quarter fiscal 2013 results. While the last quarter results reflect a definite...(
read more)
Walgreen Co. (WAG) reported net earnings of $756 million or 79 cents per share in the second quarter of fiscal 2013, higher than the year-ago net earnings of $683 million or 78...(
read more)
Linked here is a detailed quantitative analysis of Walgreen Co. (WAG). Below are some highlights from the above linked analysis:
Company Description:
Walgreen Co. is the largest U.S. retail drug...(
read more)